January 18, 2017
2 min watch
Save

VIDEO: Lampalizumab phase 3 trial progressing

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

KOLOA, Hawaii ― At Retina 2017, Steven D. Schwartz, MD, discusses the phase 3 trial investigating the possible complement cascade inhibiting effects of lampalizumab to slow the progression of geographic atrophy in AMD.